162 related articles for article (PubMed ID: 15800936)
1. BM18: A novel androgen-dependent human prostate cancer xenograft model derived from a bone metastasis.
McCulloch DR; Opeskin K; Thompson EW; Williams ED
Prostate; 2005 Sep; 65(1):35-43. PubMed ID: 15800936
[TBL] [Abstract][Full Text] [Related]
2. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
[TBL] [Abstract][Full Text] [Related]
4. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
[TBL] [Abstract][Full Text] [Related]
5. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines.
Harper ME; Goddard L; Smith C; Nicholson RI
Prostate; 2004 Jan; 58(1):13-22. PubMed ID: 14673948
[TBL] [Abstract][Full Text] [Related]
7. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.
Nagabhushan M; Miller CM; Pretlow TP; Giaconia JM; Edgehouse NL; Schwartz S; Kung HJ; de Vere White RW; Gumerlock PH; Resnick MI; Amini SB; Pretlow TG
Cancer Res; 1996 Jul; 56(13):3042-6. PubMed ID: 8674060
[TBL] [Abstract][Full Text] [Related]
8. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer.
Bhattacharyya RS; Husbeck B; Feldman D; Knox SJ
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):935-40. PubMed ID: 18760546
[TBL] [Abstract][Full Text] [Related]
9. VCaP, a cell-based model system of human prostate cancer.
Korenchuk S; Lehr JE; MClean L; Lee YG; Whitney S; Vessella R; Lin DL; Pienta KJ
In Vivo; 2001; 15(2):163-8. PubMed ID: 11317522
[TBL] [Abstract][Full Text] [Related]
10. Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft.
Rocchi P; Muracciole X; Fina F; Mulholland DJ; Karsenty G; Palmari J; Ouafik L; Bladou F; Martin PM
Oncogene; 2004 Dec; 23(56):9111-9. PubMed ID: 15489889
[TBL] [Abstract][Full Text] [Related]
11. LuCaP 35: a new model of prostate cancer progression to androgen independence.
Corey E; Quinn JE; Buhler KR; Nelson PS; Macoska JA; True LD; Vessella RL
Prostate; 2003 Jun; 55(4):239-46. PubMed ID: 12712403
[TBL] [Abstract][Full Text] [Related]
12. Establishment of two human prostate cancer cell lines derived from a single bone metastasis.
Navone NM; Olive M; Ozen M; Davis R; Troncoso P; Tu SM; Johnston D; Pollack A; Pathak S; von Eschenbach AC; Logothetis CJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2493-500. PubMed ID: 9815652
[TBL] [Abstract][Full Text] [Related]
13. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
14. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.
Snoek R; Cheng H; Margiotti K; Wafa LA; Wong CA; Wong EC; Fazli L; Nelson CC; Gleave ME; Rennie PS
Clin Cancer Res; 2009 Jan; 15(1):39-47. PubMed ID: 19118031
[TBL] [Abstract][Full Text] [Related]
15. [Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer].
Gleave M; Santo N; Rennie PS; Goldenberg SL; Bruchovsky N; Sullivan LD
Prog Urol; 1996 Jun; 6(3):375-85. PubMed ID: 8763692
[TBL] [Abstract][Full Text] [Related]
16. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process.
Craft N; Chhor C; Tran C; Belldegrun A; DeKernion J; Witte ON; Said J; Reiter RE; Sawyers CL
Cancer Res; 1999 Oct; 59(19):5030-6. PubMed ID: 10519419
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
[TBL] [Abstract][Full Text] [Related]
18. Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients.
Crnalic S; Hörnberg E; Wikström P; Lerner UH; Tieva A; Svensson O; Widmark A; Bergh A
Endocr Relat Cancer; 2010 Dec; 17(4):885-95. PubMed ID: 20688881
[TBL] [Abstract][Full Text] [Related]
19. Characterization of C4-2 prostate cancer bone metastases and their response to castration.
Pfitzenmaier J; Quinn JE; Odman AM; Zhang J; Keller ET; Vessella RL; Corey E
J Bone Miner Res; 2003 Oct; 18(10):1882-8. PubMed ID: 14584899
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of a new human prostatic cancer cell line: DuCaP.
Lee YG; Korenchuk S; Lehr J; Whitney S; Vessela R; Pienta KJ
In Vivo; 2001; 15(2):157-62. PubMed ID: 11317521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]